I Must Find a Way to Keep Heart Failure Progression From Coming
The purpose of this presentation is to highlight the recommendations made by the ACC/AHA/HFSA 2017 heart failure guidelines regarding appropriate use of sacubitril/valsartan, Ivabradine, and intravenous iron therapy. In additional, the clinical evidence that created the foundation from which these recommendations were derived will be reviewed for a more thorough understanding of the benefits associated with implementation in appropriate patients with heart failure. By reviewing the guidelines and the literature, pharmacists in attendance will be further equipped to recognize patients that may benefit from the addition of these agents to their care, recommend initiation, cessation, or avoidance of these therapies based on patient specific criteria, and participate in interdisciplinary, collaborative discussions aimed at optimizing patient care for patients with heart failure. Pharmacy technicians will be equipped with the knowledge of these medications and increased familiarity that will enhance recognition when these medications are ordered or dispensed.
Target Audience
- Pharmacists
- Pharmacy technicians
Learning Objectives
Pharmacist learning objectives
- Identify patients that may benefit from the addition of sacubitril/valsartan to their heart failure regiment
- Define the criteria that must be met in order to initiate Ivabradine in patients with heart failure
- Explain the benefit of intravenous iron therapy for patients with HF and iron deficiency anemia
Pharmacy technician learning objectives
- Recognize the different medications used to manage HF
Additional Information
Attachment | Size |
---|---|
![]() | 23.3 KB |
![]() | 122.85 KB |
Relevant financial relationships: Planning committee members and the presenter have nothing to disclose
Planning committee members

Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CEU – Attendance